SPRC

SciSparc Ltd. (SPRC) | Rumor.io

SciSparc

SPRC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,910

Bullish sentiment (50-day avg)66%

Price to earnings ratio0.05

Market capitalization113.3M

Earnings per share94.1

Dividend yield (TTM)—

Revenue (annual)856K

Net income (annual)-12.6M

Social

What share of all stock conversation is about SPRC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% new	0% +0	0% 0

Sep 23

SciSparc's subsidiary NeuroThera expanded its U.S. patent portfolio with new applications combining PEA technology with LSD, ketamine and ibogaine for mental health treatments.
The patent portfolio expansion includes three new applications covering proprietary combinations of NeuroThera's PEA technology with LSD, ketamine, and ibogaine.
SciSparc's stock price has risen 15.97% to $5.30, with a notable increase in trading volume, and some traders are optimistic about the stock's potential for further growth.

Generated by AI

Sentiment

Of the messages about SPRC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +33.33	72.44% -4.85
Bearish	0%	0%	0% -33.33	27.56% +4.85

Bullish· Jul 30

SciSparc Ltd. ($SPRC) has shown significant price appreciation, with a notable mention of its move being "nice" and having "room to expand much further".
The company's market capitalization is considered "ridiculous low", suggesting a potential for further growth.
SciSparc Ltd. ($SPRC) has formed a higher shoulder, indicating a possible continuation of its upward trend, with a potential target area of $11.20-$11.50.

Bearish· Jul 29

The price of SciSparc Ltd. (SPRC) dropped significantly, with one user experiencing a -$3 drop in a flash.
The halt in trading of SPRC can drop real fast due to its spread, and one user believes this can lead to a significant decline.
The halt in trading of SPRC has been triggered multiple times, with one user speculating that this is an attempt to prevent the price from rising.

Generated by AI

Topics

Of the messages about SPRC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	80%	80.49%	38.38%
Technical Analysis	100%	20%	19.51%	10.84%
Controversies	0%	0%	0%	0.27%
Macro	0%	0%	0%	25.33%
Analysts	0%	0%	0%	25.17%
Earnings	0%	0%	0%	0%

Announcements· Jun 4

SciSparc's subsidiary NeuroThera Labs completed the acquisition of CliniQuantum, a company using quantum simulation to identify which patients respond to drugs in clinical trials.
The acquisition was an all-share deal valued at CAD$9.46 million, with an earn-out structure up to US$2.5 million tied to patent filings.
The acquisition has led to a significant increase in SciSparc's stock price, with a 45% gain on the day of the announcement.

Technical Analysis· Jul 23

Bullish MACD crossover and rising histogram suggest improving momentum, with ideal pullback to moving averages for lower-risk entries.
Price clearing consolidation range with expanding volume, momentum favors continuation toward prior highs, monitor RSI for overbought signs.
MACD bullish divergence observed on recent swing lows, trend likely to resume if price stays above key EMAs with rising volume.

Generated by AI

Community

Of the messages about SPRC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	80%	67.65%	41.89%
Newcomers	0%	20%	32.35%	58.11%

Regulars· Jul 30

$SPRC is being considered for continuation, with one participant noting its potential for a strong move.
The regulars are optimistic about $SPRC's prospects, with one comparing it to $DFNS and noting its low market capitalization and high float.
$SPRC is being watched closely, with one participant expecting a potential "boom" after the herd takes notice, and another speculating about the possibility of a surprise move that could surpass $DFNS.

Newcomers· Jul 30

$SPRC is currently experiencing a strong upward trend, with a +17.6% increase today and a relative volume of 1.0x, indicating a significant amount of trading activity.
Newcomers are taking notice of SciSparc, with some users mentioning its recent price action and potential for further growth, citing the company's AI-related news as a possible catalyst for its success.
$SPRC has formed a higher shoulder overall, with some users identifying the 11.20-11.50 area as a potential next support level if momentum continues, and others noting its ability to bounce off lower trend line support in its rising bull channel.

Generated by AI

The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developi

6d agoYahoo! Finance Canada

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

This Strategic Engagement is Designed to Strengthen NeuroThera's U.S. Market Position, Visibility Among Key U.S. Federal Stakeholders, Reinforce the Clinical and PublicHealth Importance of Advancing New Treatment Options for Adult Tourette Syndrome T...

28d agoYahoo Finance

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Lab...

29d agomarkets.businessinsider.com

SciSparc appoints AI professor to advisory board

1mo agoInvesting.com

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market TEL AVIV, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced the addition of Prof. Carmel Domshlak, an internationally recognized artificial intelligence (“AI”) expert and professor at the Technion – Israel Institute of Technology (“Technion”), to the Company’s n

1mo agoYahoo Finance

SciSparc subsidiary publishes MDMA combination patent application

1mo agoInvesting.com

Also Discussed

Investors talking about SPRC also mention

#	Name	Attention
1	SGI Enhanced Market Leaders ETFLDRX	0%0
2	Clearmind Medicine Inc. Common SharesCMND	0%new
3	State Street My2027 Municipal Bond ETFMYMG	0%0
4	Embecta Corp.EMBC	0%new
5	F/m US Treasury 5 Year Note ETFUFIV	0%0
6	Moolec Science SAMLEC	0%new
7	BioAffinity Technologies Inc.BIAF	0%+0
8	Decent Holding Inc. Class A Ordinary SharesDXST	0.02%new
9	Bluejay Diagnostics Inc.BJDX	0%0
10	JPMorgan Healthcare Leaders ETFJDOC	0%0

SciSparc Ltd.

Healthcare
Biotechnology

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders and related conditions. Its current pipeline includes drug candidates aimed at Tourette syndrome, Alzheimer’s disease and agitation, autism spectrum disorder, status epilepticus, obstructive sleep apnea, and chronic pain. The company’s core programs are built around proprietary formulations that combine cannabinoid compounds with palmitoylethanolamide, supporting both clinical and preclinical development efforts. SciSparc also operates commercial activities through sales of hemp seed oil-based and other hemp-derived consumer products. Based in Tel Aviv, Israel, SciSparc participates in the broader specialty pharmaceutical market by advancing targeted therapies and complementing its research pipeline with product sales and development collaborations.

Website

Location

Tower A

Tel Aviv-Yafo, 6971916

Israel

Social

What share of all stock conversation is about SPRC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% new	0% +0	0% 0

Sep 23

SciSparc's subsidiary NeuroThera expanded its U.S. patent portfolio with new applications combining PEA technology with LSD, ketamine and ibogaine for mental health treatments.
The patent portfolio expansion includes three new applications covering proprietary combinations of NeuroThera's PEA technology with LSD, ketamine, and ibogaine.
SciSparc's stock price has risen 15.97% to $5.30, with a notable increase in trading volume, and some traders are optimistic about the stock's potential for further growth.

Generated by AI

Sentiment

Of the messages about SPRC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +33.33	72.44% -4.85
Bearish	0%	0%	0% -33.33	27.56% +4.85

Bullish· Jul 30

SciSparc Ltd. ($SPRC) has shown significant price appreciation, with a notable mention of its move being "nice" and having "room to expand much further".
The company's market capitalization is considered "ridiculous low", suggesting a potential for further growth.
SciSparc Ltd. ($SPRC) has formed a higher shoulder, indicating a possible continuation of its upward trend, with a potential target area of $11.20-$11.50.

Bearish· Jul 29

The price of SciSparc Ltd. (SPRC) dropped significantly, with one user experiencing a -$3 drop in a flash.
The halt in trading of SPRC can drop real fast due to its spread, and one user believes this can lead to a significant decline.
The halt in trading of SPRC has been triggered multiple times, with one user speculating that this is an attempt to prevent the price from rising.

Generated by AI

Topics

Of the messages about SPRC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	80%	80.49%	38.38%
Technical Analysis	100%	20%	19.51%	10.84%
Controversies	0%	0%	0%	0.27%
Macro	0%	0%	0%	25.33%
Analysts	0%	0%	0%	25.17%
Earnings	0%	0%	0%	0%

Announcements· Jun 4

SciSparc's subsidiary NeuroThera Labs completed the acquisition of CliniQuantum, a company using quantum simulation to identify which patients respond to drugs in clinical trials.
The acquisition was an all-share deal valued at CAD$9.46 million, with an earn-out structure up to US$2.5 million tied to patent filings.
The acquisition has led to a significant increase in SciSparc's stock price, with a 45% gain on the day of the announcement.

Technical Analysis· Jul 23

Bullish MACD crossover and rising histogram suggest improving momentum, with ideal pullback to moving averages for lower-risk entries.
Price clearing consolidation range with expanding volume, momentum favors continuation toward prior highs, monitor RSI for overbought signs.
MACD bullish divergence observed on recent swing lows, trend likely to resume if price stays above key EMAs with rising volume.

Generated by AI

Community

Of the messages about SPRC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	80%	67.65%	41.89%
Newcomers	0%	20%	32.35%	58.11%

Regulars· Jul 30

$SPRC is being considered for continuation, with one participant noting its potential for a strong move.
The regulars are optimistic about $SPRC's prospects, with one comparing it to $DFNS and noting its low market capitalization and high float.
$SPRC is being watched closely, with one participant expecting a potential "boom" after the herd takes notice, and another speculating about the possibility of a surprise move that could surpass $DFNS.

Newcomers· Jul 30

$SPRC is currently experiencing a strong upward trend, with a +17.6% increase today and a relative volume of 1.0x, indicating a significant amount of trading activity.
Newcomers are taking notice of SciSparc, with some users mentioning its recent price action and potential for further growth, citing the company's AI-related news as a possible catalyst for its success.
$SPRC has formed a higher shoulder overall, with some users identifying the 11.20-11.50 area as a potential next support level if momentum continues, and others noting its ability to bounce off lower trend line support in its rising bull channel.

Generated by AI

SciSparc

Social

Sep 23

Bullish· Jul 30

Bearish· Jul 29

Announcements· Jun 4

Technical Analysis· Jul 23

Regulars· Jul 30

Newcomers· Jul 30

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

SciSparc appoints AI professor to advisory board

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

SciSparc subsidiary publishes MDMA combination patent application

Also Discussed

SciSparc Ltd.

Company Information

Location

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

SciSparc appoints AI professor to advisory board

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

SciSparc subsidiary publishes MDMA combination patent application

Also Discussed

Social

Sep 23

Bullish· Jul 30

Bearish· Jul 29

Announcements· Jun 4

Technical Analysis· Jul 23

Regulars· Jul 30

Newcomers· Jul 30